Filip Janku<p>Relatively hopeful data from MARIO-3 (eganelisib, atezolizumab and nab-paclitaxel in 1L mTNBC. It has to be viewed cautiously as comparisons are made to historical population of IM130 but for now PI3K-gamma inhibition appears to be resurrected <a href="https://med-mastodon.com/tags/TNBC" class="mention hashtag" rel="tag">#<span>TNBC</span></a> <a href="https://med-mastodon.com/tags/PI3Kgamma" class="mention hashtag" rel="tag">#<span>PI3Kgamma</span></a> <a href="https://med-mastodon.com/tags/EndCancer" class="mention hashtag" rel="tag">#<span>EndCancer</span></a></p><p><a href="https://www.businesswire.com/news/home/20221114005336/en/Infinity-Pharmaceuticals-Provides-MARIO-3-Update-in-Patients-with-Front-Line-Metastatic-Triple-Negative-Breast-Cancer-Suggesting-Potential-Long-Term-Patient-Benefit-of-Eganelisib" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://www.</span><span class="ellipsis">businesswire.com/news/home/202</span><span class="invisible">21114005336/en/Infinity-Pharmaceuticals-Provides-MARIO-3-Update-in-Patients-with-Front-Line-Metastatic-Triple-Negative-Breast-Cancer-Suggesting-Potential-Long-Term-Patient-Benefit-of-Eganelisib</span></a></p>